LungLife AI Inkomsten in het verleden
Verleden criteriumcontroles 0/6
LungLife AI has been growing earnings at an average annual rate of 7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 73.5% per year.
Belangrijke informatie
7.0%
Groei van de winst
57.6%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 11.5% |
| Inkomstengroei | -73.5% |
| Rendement op eigen vermogen | -56.3% |
| Nettomarge | -15,403.4% |
| Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
We Think LungLife AI (LON:LLAI) Needs To Drive Business Growth Carefully
Dec 08
We Think LungLife AI (LON:LLAI) Needs To Drive Business Growth Carefully
Aug 12Here's Why LungLife AI (LON:LLAI) Must Use Its Cash Wisely
Feb 09Here's Why We're A Bit Worried About LungLife AI's (LON:LLAI) Cash Burn Situation
Oct 08Opbrengsten en kosten
Hoe LungLife AI geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -4 | 4 | 0 |
| 31 Mar 24 | 0 | -5 | 5 | 0 |
| 31 Dec 23 | 0 | -5 | 5 | 0 |
| 30 Sep 23 | 0 | -6 | 6 | 0 |
| 30 Jun 23 | 0 | -6 | 6 | 0 |
| 31 Mar 23 | 0 | -7 | 7 | 0 |
| 31 Dec 22 | 0 | -8 | 7 | 0 |
| 30 Sep 22 | 0 | -7 | 8 | 0 |
| 30 Jun 22 | 0 | -7 | 8 | 0 |
| 31 Mar 22 | 0 | -7 | 7 | 0 |
| 31 Dec 21 | 0 | -7 | 6 | 0 |
| 30 Sep 21 | 0 | -7 | 5 | 0 |
| 30 Jun 21 | 0 | -7 | 4 | 0 |
| 31 Mar 21 | 0 | -6 | 3 | 0 |
| 31 Dec 20 | 0 | -5 | 3 | 0 |
Kwaliteitswinsten: LLAI is currently unprofitable.
Groeiende winstmarge: LLAI is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: LLAI is unprofitable, but has reduced losses over the past 5 years at a rate of 7% per year.
Versnelling van de groei: Unable to compare LLAI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: LLAI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: LLAI has a negative Return on Equity (-56.31%), as it is currently unprofitable.